All In MedTech

Device Trial Radar · NCT04033081

Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®

Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 30, 2020

Primary completion

Jan 2027

Study completion Apr 2030

Sponsor

Lead sponsor
CivaTech OncologyNot on our public-company list
Sponsor type
Industry
First posted
Jul 25, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This patient study will determine the safety and toxicity of a permanently implantable brachytherapy source - CivaSheet® - which is designed to deliver a therapeutic dose of low dose rate (LDR) radiation with polymer encased Palladium-103. CivaSheet will be implanted in sarcoma patients with disease presenting in the retroperitoneum, abdomen, pelvis and trunk.

Conditions

  • Sarcoma

Interventions

  • CivaSheetDevice

    Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of acute toxicityTime frame: 90 days post implant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.